TESSP1 Inhibitors
TESSP1 inhibitors encompass a range of small-molecule compounds that indirectly affect the activity of TESSP1 by targeting various cellular signaling pathways and kinases. For instance, Imatinib, a tyrosine kinase inhibitor, suppresses cellular activities that may lead to TESSP1 activation by interfering with downstream signaling cascades. Similarly, Vemurafenib specifically inhibits the BRAF V600E mutation within the MAPK/ERK pathway, a critical route for cell proliferation, which could also be responsible for triggering TESSP1 activation. Trametinib and Sorafenib, both acting on the MAPK/ERK pathway albeit at different points, prevent the initiation of signaling processes that could potentially activate TESSP1. Furthermore, Palbociclib disrupts cell cycle progression by inhibiting CDK4/6, which might affect TESSP1 activity that is regulated via cell cycle-dependent signals.
Additional examples of TESSP1 inhibitors include Dasatinib and Nilotinib, which block the Src family and certain tyrosine kinases, respectively, thereby impeding the upstream regulatory mechanisms that could lead to TESSP1 activation. Olaparib's role as a PARP inhibitor disrupts the DNA damage response, a process that might otherwise contribute to TESSP1's activation. Agents such as Lapatinib, which targets EGFR and HER2/neu, Crizotinib, which inhibits ALK and ROS1, and Bortezomib, a proteasome inhibitor, all contribute to the milieu of inhibitory influences that decrease the likelihood of TESSP1 becoming functionally active. These inhibitors collectively showcase the varied approaches available to modulate TESSP1 activity through the inhibition of distinct yet interconnected biological pathways.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
A tyrosine kinase inhibitor that targets specific tyrosine kinases involved in cell growth and survival. By inhibiting these kinases, Imatinib decreases cellular activities that could otherwise contribute to the activation of TESSP1 through downstream signaling cascades. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
A BRAF kinase inhibitor that blocks the function of the BRAF V600E mutation, a variant that can activate the MAPK/ERK pathway, leading to cellular proliferation. Inhibition of this pathway would prevent the potential activation of TESSP1 associated with this signaling route. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that acts by binding to FKBP12 and blocking mTORC1, leading to the inhibition of cellular growth and proliferation signals that may indirectly regulate TESSP1 activity through growth factor signaling. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
A MEK inhibitor that indirectly affects TESSP1 by inhibiting the MAPK/ERK pathway, which is involved in cell cycle progression and differentiation. This pathway’s inhibition could prevent the activation of TESSP1. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
A CDK4/6 inhibitor that interrupts the cell cycle, thereby potentially affecting the expression or activation of TESSP1 through cell cycle-regulated signaling pathways. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
A multikinase inhibitor that targets several receptor tyrosine kinases and downstream signaling pathways that could be involved in the regulation of TESSP1 activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
A Src kinase inhibitor that blocks the Src family of kinases, which could be upstream regulators of TESSP1 through various signaling pathways that influence cell adhesion and migration. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
A selective inhibitor of certain tyrosine kinases, which could potentially prevent the activation of TESSP1 through the inhibition of kinase-mediated signaling pathways. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
A PARP inhibitor that interferes with DNA repair mechanisms. By affecting the cellular stress response, it could indirectly prevent the activation of TESSP1 which could be associated with DNA damage response pathways. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
A dual tyrosine kinase inhibitor that targets EGFR and HER2/neu, potentially affecting TESSP1 activity through the inhibition of growth factor signaling pathways. | ||||||